India’s Two-Sided Antibiotic Challenge

Context: The article analyses India’s simultaneous overuse of high-resistance-risk antibiotics, inadequate access to appropriate medicines and weak surveillance across human and food-animal health.

Sources:

• “India using too many powerful antibiotics meant for specific infections, says global Lancet study,” The Indian Express, July 22, 2026. Read the article
• “Domestic antibiotic use in food-animals needs monitoring despite export safeguards,” Down To Earth, July 21, 2026.

Core Points

• WHO classifies antibiotics into Access, Watch and Reserve groups according to their therapeutic role and resistance risk.
• Access antibiotics are preferred first-line treatments for common infections. Watch antibiotics have a higher resistance potential and should be limited to specified indications. Reserve antibiotics are last-resort treatments for multidrug-resistant infections.
• A Lancet Public Health study estimates that India requires 14.7 defined daily doses per 1,000 people per day but consumes approximately 18.3.
• India uses an estimated 9.3 daily doses of Watch antibiotics against a modelled requirement of six.
• Access-antibiotic consumption is estimated at 4.5 daily doses against a requirement of 7.8, while Reserve consumption is 0.19 against an estimated requirement of 0.99.
• Access medicines constitute only 27% of consumption against an estimated requirement of 52.3%.
• Overuse and inadequate access coexist: some patients receive unnecessarily broad antibiotics, while others lack appropriate first-line or last-resort treatment.
• India’s hospital survey found that only 6% of prescriptions were supported by microbiological evidence and more than half were issued for prophylaxis rather than treatment.
• Unnecessary duplicate coverage, prolonged surgical prophylaxis and extensive intravenous administration add costs and toxicity without necessarily improving outcomes.
• In food-animal production, export safeguards prohibit specified antimicrobials and growth-promotion uses, but comparable surveillance of farms serving the domestic market remains inadequate.
• Resistance can spread between humans, animals and the environment through food, direct contact, wastewater, manure, soil and mobile resistance genes.

Prelims Relevance

• A defined daily dose is a standardised statistical unit used to compare medicine consumption; it is not necessarily the dose prescribed to an individual patient.
• Antimicrobial resistance develops in microorganisms, not in the human or animal receiving treatment.
• Antibiotics act against bacteria; the wider category of antimicrobials also includes antiviral, antifungal and antiparasitic medicines.
• One Health recognises the interdependence of human, animal and environmental health.

Mains Relevance

• GS II: Public health regulation, access to medicines and hospital governance.
• GS III: Antimicrobial resistance, diagnostics, livestock management and environmental contamination.

Supporting Fact Box

• Global target: The 2030 international target seeks at least 70% of human antibiotic consumption from the Access group, taking national circumstances into account.
• National hospital data: Across 66 tertiary-care institutions in 2024, Access antibiotics accounted for 42% of consumption, Watch antibiotics 53%, Reserve antibiotics 2% and non-recommended combinations 3%.
• Stewardship: Antimicrobial stewardship uses diagnostic evidence, treatment guidelines, audit and review to improve the selection, dosage, route and duration of therapy.
• Residue and resistance: A food sample complying with a residue limit does not establish that resistant bacteria or resistance genes are absent from the production system.
• FSSAI limits: Most prohibited veterinary drugs have an extraneous maximum residue limit of 0.001 mg/kg; chloramphenicol has a lower limit of 0.0003 mg/kg.